Nonselective tyrosine kinase inhibitors (TKIs) have shown limited benefit in NSCLC patients with HER2 mutation, with objective response rates (ORRs) ranging from 0% to 19% [10]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.